August 3, 2018 08:09 AM EDT
Pharma

Roche gets some reg­u­la­to­ry love for its break­through quest on a PhI­II Hunt­ing­ton's drug

John Carroll

Editor & Founder

Roche got a boost to­day in its quest to steer a po­ten­tial­ly land­mark Hunt­ing­ton’s drug through piv­otal de­vel­op­ment. The EMA hand­ed Roche its

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

MIT sci­en­tists’ AI mod­el one-ups Al­phaFold 3, takes on ‘fun­da­men­tal is­sue’ in drug R&D

Is there still hope for Sum­mit's can­cer drug buried in the da­ta?

Bio­phar­ma lead­ers carv­ing a path for the in­dus­try’s LGBTQ+ com­mu­ni­ty

EMA con­sid­ers se­ri­ous eye con­di­tion a ‘very rare’ side ef­fect of semaglu­tide 

Biotech ranks as Chi­na’s best shot to sur­pass US in emerg­ing tech, re­port finds

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times